Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: Implications for the treatment of cutaneous lymphoprohferatlve and inflammatory disorders

Journal of Investigative Dermatology

Volumn 111, Issue 2, 1998, Pages 327-332

  Fox, Floyd E ^a,b   Niu, Zhutian ^a   Tobia, Alfonso ^c   Rook, Alain H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTOCOR INC   (United States)

^c VimRx Pharmaceuticals   (United States)

Author keywords

Apoptosis; CTCL; Photoactivation

Indexed keywords

HYPERICIN; METHOXSALEN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEAR CELL; PHOTOACTIVATION; PRIORITY JOURNAL; SKIN INFLAMMATION; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

EID: 0031903830     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00278.x     Document Type: Article

References (48)

1. Agostinis P, Donella-Deana A, Cuveele J, Vandenbogaerde A, Sarno S, de Merlevede W: A comparative analysis of the photosensitized inhibition of growth-factor regulated protein kinases by hypericin-derivatives. Biochem Biophys Res Comms 220:613-617, 1996
2. Andreoni A, Colasanti A, Colasanti P, Mastrocinque M, Riccio P, Roberu G: Laser photosensitization of cells by hypericin. Photochem Photobiol 59:529-533, 1994
3. Bladt S, Wagner H: Inhibition of MAO by fraction and constituents of hypericum extract. J Geriatric Psychiatry Neurol 7 (Suppl. 1):S57-S59, 1994
4. Carpenter S, Kraus GA: Photosensitization is required for inactivation of equine infectious anemia virus by hyperium. Photochem Photobiol 53:169-174, 1991
5. Carpenter S, Fehr MJ, Kraus GA, Petrich JW: Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight. Proc Natl Acad Sci USA 91:12273-12277, 1994
6. Chung PS, Saxton RE, Paiva MB, et al: Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 104:1471-1476, 1994
7. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Law RE, Apuzzo MI: Hypertemia a potential antiglioma therapy [published erratum appears in Neurosurgery 35:993, 1994]. Neurosurgery 35:705-710, 1994
8. Diwu Z: Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol 61:529-539, 1995
9. Diwu Z, Lown JW: Photosensitization with anticancer agents 17: The EPR study of photodynamic action of hypericin. Free Rad Biol Med 14:209-215, 1993
10. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G: Sezary syndrome T cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta-chain). Blood 88:1383-1389, 1996
11. Duran N, Song PS: Hyperium and its photodynamic action. Photochem Photobiol 43:677-680, 1986
12. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A: Photodynamic effects of hypertein on lipid peroxidation and antioxidant status in melonoma cells. Photochem Photobiol 64:375-381, 1996
13. Hamilton HB, Hinton DR, Law RE, et al: Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurgery 85:329-334, 1996
14. Hudson JB, Lopez-Bazzocchi I, Towers GH: Antiviral activities of hypericin. Antiviral Res 15:101-112, 1991
15. Jarvis WD, Turner AJ, Povirk TF, Travlor RS, Grant S: Induction of apoptotic DNA fragmentation and cell death in HI-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 54:1707-1714, 1994
16. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I: Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrobial Agents Chemotherapy 40:2087-2093, 1996
17. Koren H, Schenk GM, Jindia RH, et al: Hypericin in phototherapy. J Photochem Photobiol B. Biol 36:113-119, 1996
18. Kraus GA, Pratt D, Tossberg J, Carpenter S: Antiretroviral activity of synthetic hypericin and related analogs. Biochem Biophys Res Comms 172:149-153, 1990
19. Lavie G, Valentine F, Levin B, et al: Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 86:5963-5967, 1989
20. Lavie G, Mazur Y, Lavie D, Meruelo D: The chemical and biological properties of hypericin - a compound with a broad spectrum of biological activities [published erratum appears in Med Res Rev 15:259, 1995]. Med Res Rev 15:111-119, 1995
21. Lenard J, Rabson A, Vanderoef R: Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci USA 90:158-162, 1993
22. Lessin SR, Rook AH, Rovera G: Molecular diagnosis of cutaneous T cell lymphoma: polymerase chain reaction amplification of T cell antigen receptor beta-chain gene rearrangements. J Invest Dermatol 96:299-302, 1991
23. Laebes I, Mazur Y, Freeman D, et al: A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 195:77-86, 1991
24. Lopez-Bazzocchi I, Hudson JB, Towers GH: Antiviral activity of the photoactive plant pigment hypericin. Photochem Photobiol 54:95-98, 1991
25. Meruelo D, Lavie G, Lavie D: Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 85:5230-5234, 1988
26. Migita K, Eguchi K, Kawabe Y, Tsukada T, Ichinose Y, Nagataki S: Defective TCR-mediated signaling in anergic T cells. J Immunol 155:5083-5087, 1995
27. Perovic S, Muller WE: Pharmacological profile of hypericum extract Effect on serotonin uptake by postsynaptic receptors. Arzneumittel-Forschung 45, 1145-1148, 1995
28. Rook AH, Lessin SR, Jaworsky C, Singh A, Vowels BR: Immunopathogenesis of cutaneous T cell lymphomas: Abnormal cytokine production by Sczary T cells. Arch Dermatol 129:486-489, 1993.
29. Rook AH, Kubin M, Cassin M, et al: 11-12 reverses cytokine and immune abnormalities in Sczary syndrome. J Immunol 154:1491-1498, 1995
30. Sgone R, Boeck G, Dietrich H, Gruber J, Recheis H, Wick G: Simultaneous determination of cell surface antigens and apotosis. Trends Genet 10:41-42, 1994.
31. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I: Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract 11 160 an healthy volunteers. J Geriatrn Psychiatry Neurol 7 (Suppl. 1):S47-S53, 1994
32. Stern RS, Nichols KT, Vakeva TH: Malignant melanoma in patients treated for psortasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). New England J Med 336:1041-1045, 1997
33. Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T: Hypericin and pseudohypericin specifically inhibit protein kinase C. possible relation to their antiretroviral activity. Biochem Biophys Res Comms 165:1207-1212, 1989
34. Tang J, Colacino JM, Larsen SH, Spitzer W: Viruental activity of hypericin against enveloped and non enveloped DNA and RNA viruses. Antiviral Res 13:313-325, 1990
35. Thomas C, Pardini RS: Oxygen dependence of hypericin induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol 55:831-837, 1992
36. Thomas C, MacGill RS, Miller GC, Pardini RS: Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succmoxidase. Photochem Photobiol 55:47-53, 1992
37. Utsumi T, Okuma M, Kanno T, Yasuda T, Kobuchi H, Horton AA, Utsumi K: Light dependent inhibition of protein kinase C and superoxide generation of neutrophils by hypericin, an antiretroviral agent. Arch Biochem Biophysics 316:493-497, 1995
38. Van de Kerkhof PC, de Rooij MJ: Multiple squamous cell carcinoma in a psoriatic patient following high dose photochemotherapy and cyclosporin treatment: responce to long-term acitretin maintanance. Br J Dermatol 136:275-278, 1997
39. VanderWerf OM, Saxton RE, Chang A, et al: Hypericin: a new laser phototargeting agent for human cancer cells. Laryngoscope 106:479-483, 1996
40. Wang XM, McNiff JM, Klump V, Asgata M, Gasparto FP: An unexpected spectrum of p53 mutations from squamous cell carcinomas in psoriasis patients treated with PUVA. Photochem Photobiol 66:294-299, 1997
41. Weinberg JM, Jaworsky C, Benoit BM, Telegan B, Rook AH, Lessin SR: The clonal nature of circulating Sezary cells. Blood 86:4257-4262, 1995
42. Weiss LM, Wood GS, Hu E, Abel EA, Hoppe RT, Sklar J: Detection of clonal T cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoidez: Sezary syndrome. J Invest Dermatol 92:601-604, 1989
43. Whittaker SJ, Smith NP, Jones RR, Luzzatto I: Analysis of beta, gamma, and delta T cell receptor genes in mycosis fungoides and Sezary syndrome. Cancer 68:1572-1582, 1991
44. deWitte P, Van Agostitus P, I J, Merlevede W, Vandenheede JR: Inhibition of epidermal growth fector receptor tyrosine kinase activity by hypericin. Biochemical Pharmacology 46:1929-1936, 1993
45. Wolff-Sneedorff A, Ralfkiaer E, Thomsen K, Vejlsgaard GI: Analysis of T cell receptor beta-chain genes by Southern blotting in known and suspected cutaneous T cell lymphomas. A study of 67 samples from 32 patients. Clin Exp Dermatol 20:115-122. 1995
46. Zelickson BD, Peters MS, Muller SA, Thibodeau SN, Lust JA, Quam LM, Pittelkow MR: T cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. J Am Acad Dermatol 25:787-796, 1991
47. Zhang W, Lawa RE, Hintona DR, Su Y, Couldwell WT: Growth inhibition and apoptosis in human neuroblastoma SK N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Cancer Lett 96:31-35, 1995
48. Zhang W, Hinton DR, Surnock AA, Couldwell WT: Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical responce in vitro: case report. Neurosurgery 38:587-591, 1996.